Go to the M. D. Anderson Home Page

Back to the PTSG Home Page


News and Progress
Pancreatic Cancer - Frequently Asked Questions
Diagnosis and Treatment
Clinical Studies

Category A

Category B
Category C
Category D
Who are the Pancreatic Tumor Study Group specialists?
How to refer a patient for evaluation
Pancreas Cancer Survivors
From Bench to Bedside: Basic Science Research
PTSG Top Web Picks


Clinical Studies for
Patients with Pancreatic Cancer
Category C


These studies are for patients with locally advanced disease considered to be surgically unresectable


Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody C225 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer (Protocol ID99-147)

This protocol is closed to new patient entry.
Study Chairman: James L Abbruzzese, MD
Study Sponsor: ImClone Systems, Inc.
Phase II Study of Gemcitabine-based Chemoradiation and TNP-470 for Patients with Locally-Advanced, Non-metastatic Adenocarcinoma of the Pancreas. (Protocol ID98-248)

This protocol is open and accepting new patients.

Study Chairman: Douglas B Evans, MD
Study Co-Chairman: Robert A Wolff, MD
Study Sponsor: MDACC

Dot.gif (172 bytes) Rationale

Dot.gif (172 bytes) Eligibility Criteria

A Phase I Study of Concomitant Gemzar (Gemcitabine) and Rapid-Fractionation External-Beam Radiation Therapy with 3-D Conformal (Intensity Modulated) Treatment Planning for Patients with Unresectable Adenocarcinoma of the Pancreatic Head. (Protocol ID99-289)

This protocol is on hold pending review of preliminary data.

Study Chairman: Christopher H Crane, MD
Study Sponsor: MDACC

Schema: Alternating dose escalation of radiation and gemcitabine using IMRT.

Gemcitabine: 1 dose per week for 7 weeks.

Radiation: Begins on day 4 after Gemcitabine.

Rationale

Eligibility Criteria